arrow_back Back to App

Support for New Drugs Against Resistant Bacteria and Fungi in Hospitals

This act aims to encourage the development and use of new drugs to combat resistant bacteria and fungi. Hospitals meeting specific conditions will receive additional payments for using these drugs, which should improve treatment for serious infections. Furthermore, the act allocates funds for antibiotic stewardship programs in hospitals and mandates a study on barriers to the development of these crucial drugs.
Key points
Additional payments for hospitals using new drugs for resistant infections, potentially improving access to effective treatment.
Financial support for hospital antibiotic stewardship programs, especially in smaller facilities, to limit the spread of resistant bacteria.
A study on the reasons hindering the development of new drugs for resistant infections, aiming to facilitate the creation of effective therapies in the future.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_4127
Sponsor: Rep. Davis, Danny K. [D-IL-7]
Process start date: 2021-06-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

DISARM Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4127.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-06-24.

What are the main provisions?

Key points include:

  • Additional payments for hospitals using new drugs for resistant infections, potentially improving access to effective treatment.
  • Financial support for hospital antibiotic stewardship programs, especially in smaller facilities, to limit the spread of resistant bacteria.
  • A study on the reasons hindering the development of new drugs for resistant infections, aiming to facilitate the creation of effective therapies in the future.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Davis, Danny K. [D-IL-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health